Tech Company Financing Transactions
Neuvivo Funding Round
Neuvivo, operating out of Palo Alto, secured $11 million in investment from Primestreet Capital.
Transaction Overview
Company Name
Announced On
6/15/2023
Transaction Type
Venture Equity
Amount
$11,000,000
Round
Undisclosed
Investors
Primestreet Capital (Lead Investor)
Proceeds Purpose
The Company will use the funds to Develop Treatment for ALS.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
530 Lytton Ave 214
Palo Alto, CA 94301
USA
Palo Alto, CA 94301
USA
Phone
Website
Email Address
Overview
Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We are investigating a patented macrophage-targeted technology, NP001, designed to address chronic inflammation, a key factor in the progressive loss of motor function in ALS. To date, the treatment has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are diligently working to move this compound toward regulatory approval, with the goal of delivering an effective new treatment to reduce the suffering caused by ALS.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Arasteh Azhir
Chief Financial Officer
Bruce Kaufman
Chief Medical Officer
Bruce Forrest
Chief Scientific Officer
Michael McGrath
Browse more venture capital transactions:
Prev: 6/15/2023: Nelly venture capital transaction
Next: 6/15/2023: Avalon venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We record every notable VC transaction. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs